OrbisResearch.com has published new research report on “Pulmonary Drug Delivery Systems: Technologies and Global Markets” to its database.
Pulmonary drug delivery is an alternative to oral drug delivery. Pulmonary drug delivery is primarily advantageous for the treatment of respiratory diseases due to systemic administration via fast absorption by the alveolar region. The pulmonary drug delivery method depends on the development of simple, cost effective and easy to use devices. These devices are designed to facilitate consistent drug delivery with increased lung penetration and multi-dosage facilities. Currently, manufacturers are concentrating on the development of small, portable devices that encourage higher patient compliance. The World Health Organization (WHO) estimates that there were approximately 251 million people
suffering from COPD globally in 2016. It is estimated by the WHO that nearly 3.17 million deaths occurred in 2015 due to the disease itself. The primary cause of the disease is smoking tobacco. The growing number of smokers in developing economies is increasing the incidence of the disease.
Get a PDF Sample of this Report @ http://orbisresearch.com/contacts/request-sample/2124091?utm_source=shreyas
The market for pulmonary drug delivery systems is witnessing growth due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses. Other factors that are driving the growth of themarket are the emergence of novel inhaler designs and increased use of non-invasive drug delivery methods.
The pulmonary drug delivery systems market is estimated at REDACTED in 2017, growing at acompound annual growth rate (CAGR) of REDACTED to reach REDACTED in 2022.
Enquiry before buying report @ http://orbisresearch.com/contacts/enquiry-before-buying/2124091?utm_source=shreyas
This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, research and development pipeline, and blockbuster drugs.
In the report the regulatory scenario of pulmonary drug delivery systems is discussed for device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are analyzed in the Pipeline Analysis section.
A discussion of the major players is included in the Competitive Landscape section. The Competitive Landscape section provides trends in product launch, collaborations, mergers and acquisitions, and other agreements. Company profiles of major players operating in the pulmonary drug delivery systems market are included with an overview, key product offerings, financials, strategies, strength, weakness, opportunities and threats (SWOT) and developments. The report will be useful for analysis of the leading products and will enable readers to recognize growing brands, key device types and leading manufacturing companies with significant market share.
Access the complete report with TOC & List of Tables @ http://orbisresearch.com/reports/index/pulmonary-drug-delivery-systems-technologies-and-global-markets?utm_source=shreyas
– 74 tables
– A detailed overview and analysis of the global markets for pulmonary drug delivery systems
– Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
– Assessments of pulmonary drug delivery systems by regions, delivery systems/types, and disease areas
– A look at the regulatory environment, which has been a driving force in the healthcare industry
– Reviews of key developments, novel product innovations, and recent strategic industry activities of major players across various product categories
– Detailed profiles of major vendors in the market, including 3M Pharmaceuticals Inc., AstraZeneca plc, Cipla Inc., GlaxoSmithKline plc and Lupin Ltd
- 3M PHARMACEUTICALS, INC.
- ASTRAZENECA PLC
- BOEHRINGER INGELHEIM GMBH
- CIPLA, INC.
- REDDY’S LABORATORIES LTD.
- GLAXOSMITHKLINE PLC
- KONINKLIJKE PHILIPS N.V. (RESPIRONICS, INC.)
- LUPIN, LIMITED
- MYLAN N.V.
- NOVARTIS AG
- OMRON CORPORATION
- PFIZER, INC.
- PULMATRIX, INC.
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- VECTURA GROUP PLC
Table of Content
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Chapter 4 Global Flexible Foam Market Breakdown by Form Factor
Chapter 5 Global Flexible Foam Market Breakdown by Type
Chapter 6 Global Flexible Foam Market Breakdown by Application
Chapter 7 Global Flexible Foam Market Breakdown by End User
Chapter 8 Global Flexible Foam Market Breakdown by Region
Chapter 9 Patent Review and New Developments
Chapter 10 Analysis of Market Opportunities
Chapter 11 Company Profiles
Chapter 12 Appendix A: Abbreviation
Chapter 13 Appendix B: Sources
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019